![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01931-z/MediaObjects/41392_2024_1931_Fig6_HTML.png)
glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]
Description
Understanding what is changing requires moving beyond the drug itself and examining how its meaning shifts depending on why it is prescribed
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Dapagliflozin in patients with chronic kidney disease
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://www.nejm.org/cms/10.1056/NEJMcibr2409089/asset/1f854e14-bfd6-40e1-8b1c-03461c2a1ab4/assets/images/large/nejmcibr2409089_f1.jpg)
2018Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://www.mdpi.com/molecules/molecules-28-01369/article_deploy/html/images/molecules-28-01369-g001-550.jpg)
Testa G, Mora-Maltas B, Camacho-Barcia L, Granero R, Lucas I, Agera Z, et al
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://medrac.web.unc.edu/wp-content/uploads/sites/22579/2025/03/image-6.png)
CagriSema: Doubling Down CagriSema is a combination drug that pairs semaglutide (the ingredient in Ozempic) with another hormone called amylin
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-024-02300-6/MediaObjects/592_2024_2300_Fig1_HTML.png)
The ESC 2023 guidelines introduced the SCORE2-Diabetes algorithm to estimate the 10-year CVD risk in patients with T2D
![glp-1 moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1_cellular_moa.png)
